Lu177DotatateVariants_CommercialRadioligandProductMap
Lu
ℹ️ Utility checks critical parameters of lutetium-177 dotatate:
• Radiochemical purity (≥95%)
• Free Lu-177 (≤2%)
• Colloidal Lu-177 (≤1%)
• Specific activity (≥40 GBq/μmol)
• pH (3.5-5.5)
• Endotoxins (≤175 EU/vial)
• Sterility
• Radionuclidic purity (≥99.9%)
• Lu-177m impurity (≤0.05%)
⚠️ CRITICAL: Free Lu-177 accumulates in bone marrow!
Colloidal Lu-177 accumulates in liver/spleen!
Lu-177m (T½=160 days) creates prolonged radiation burden!
Usage:
Lu177DotatateVariantsQualityChecker.exe → demo mode (console output)
Lu177DotatateVariantsQualityChecker.exe input.csv output.json → evaluate your data
Input format:
BatchNumber,CommercialProduct,RadiochemicalPurityPercent,FreeLu177Percent,ColloidalLu177Percent,SpecificActivityGBqPerUmol,pH,EndotoxinsEUPerVial,SterilityTest,RadionuclidicPurityPercent,Lu177mImpurityPercent
Example (sterility: 0=sterile, 1=contaminated):
LU177-DOTA-2026-001,Lutathera,99.2,0.5,0.3,55.0,4.5,45.0,0,99.95,0.02
Supported products:
• Lutathera — original Novartis product
• Generic — generic versions of Lu-177 Dotatate
• Custom — custom products for clinical trials
— WHY IS THIS NEEDED?
Lutetium-177 Dotatate — widely used radiopharmaceutical for neuroendocrine tumor therapy:
• Lu-177 half-life: 6.65 days — optimal for therapy
• Beta radiation (0.497 MeV max) — effective tumor cell destruction
• Gamma radiation (113 and 208 keV) — allows imaging (SPECT/CT)
• Dotatate — somatostatin analog, binds to SSTR2 receptors on tumor cells
• Clinically proven efficacy in progressive GEP-NETs
⚠️ CRITICAL:
• Radiochemical purity ≥95% — ensures radiation delivery to tumor cells
• Free Lu-177 ≤2% — UNBOUND lutetium accumulates in BONE MARROW, causing myelosuppression!
• Colloidal Lu-177 ≤1% — COLLOIDS accumulate in liver and spleen, causing toxicity!
• Specific activity ≥40 GBq/μmol — ensures sufficient therapeutic dose
• pH 3.5-5.5 — critical for complex stability and blood compatibility
• Endotoxins ≤175 EU/vial — critical for IV administration!
• Sterility — MANDATORY for all parenteral forms!
• Radionuclidic purity ≥99.9% — minimizes non-target irradiation
• Lu-177m impurity ≤0.05% — CRITICAL! Lu-177m (T½=160 days) creates PROLONGED RADIATION BURDEN without therapeutic benefit
Key features:
• Check of all lutetium-177 forms (bound, free, colloidal)
• Specific activity control for therapeutic efficacy
• Specific control of Lu-177m impurity (metastable state)
• Support for different commercial products (Lutathera, generics, custom)
• Comprehensive check of radionuclidic and radiochemical parameters
Critical parameters:
• Radiochemical purity: ≥95.0%
• Free Lu-177: ≤2.0%
• Colloidal Lu-177: ≤1.0%
• Specific activity: ≥40 GBq/μmol
• pH: 3.5–5.5
• Endotoxins: ≤175 EU/vial
• Sterility: no microbial growth
• Radionuclidic purity: ≥99.9%
• Lu-177m impurity: ≤0.05%
💡 Usage tips:
1. Radiochemical purity controlled by HPLC or TLC
2. Free and colloidal Lu-177 separated by chromatography methods
3. Lu-177m determined by gamma spectrometry (228 keV peak)
4. Specific activity calculated from measured activity and peptide amount
5. If free Lu-177 >2% detected — batch rejected (myelosuppression risk)!
6. Lu-177m especially dangerous due to 160-day half-life — even 0.05% is unacceptable!
⚠️ Note: Lu-177 Dotatate is ONE OF THE MOST EFFECTIVE therapeutic radiopharmaceuticals for neuroendocrine tumors. Product quality is critically important: free lutetium causes myelosuppression, colloidal causes hepatotoxicity, and Lu-177m creates unnecessary prolonged radiation burden. Control of all these parameters is MANDATORY for clinical use.
input.csv
BatchNumber,CommercialProduct,RadiochemicalPurityPercent,FreeLu177Percent,ColloidalLu177Percent,SpecificActivityGBqPerUmol,pH,EndotoxinsEUPerVial,SterilityTest,RadionuclidicPurityPercent,Lu177mImpurityPercent LU177-DOTA-2026-001,Lutathera,99.2,0.5,0.3,55.0,4.5,45.0,0,99.95,0.02 LU177-DOTA-2026-002,Generic,97.8,1.2,0.5,48.0,4.2,80.0,0,99.92,0.03 LU177-DOTA-2026-003,Custom,96.5,1.8,0.8,42.0,4.8,120.0,0,99.90,0.04
Lu177DotatateVariants_CommercialRadioligandProductMap — Documentation
input.csv and *.description.txt. Package folder: Cardiology QC Suite.Utility description
Lu-177 Dotatate Variants Quality Checker — Lutetium-177 Dotatate (commercial radioligands)
ℹ️ Utility checks critical parameters of lutetium-177 dotatate:
• Radiochemical purity (≥95%)
• Free Lu-177 (≤2%)
• Colloidal Lu-177 (≤1%)
• Specific activity (≥40 GBq/μmol)
• pH (3.5-5.5)
• Endotoxins (≤175 EU/vial)
• Sterility
• Radionuclidic purity (≥99.9%)
• Lu-177m impurity (≤0.05%)
⚠️ CRITICAL: Free Lu-177 accumulates in bone marrow!
Colloidal Lu-177 accumulates in liver/spleen!
Lu-177m (T½=160 days) creates prolonged radiation burden!
Usage:
Lu177DotatateVariantsQualityChecker.exe → demo mode (console output)
Lu177DotatateVariantsQualityChecker.exe input.csv output.json → evaluate your data
Input format:
BatchNumber,CommercialProduct,RadiochemicalPurityPercent,FreeLu177Percent,ColloidalLu177Percent,SpecificActivityGBqPerUmol,pH,EndotoxinsEUPerVial,SterilityTest,RadionuclidicPurityPercent,Lu177mImpurityPercent
Example (sterility: 0=sterile, 1=contaminated):
LU177-DOTA-2026-001,Lutathera,99.2,0.5,0.3,55.0,4.5,45.0,0,99.95,0.02
Supported products:
• Lutathera — original Novartis product
• Generic — generic versions of Lu-177 Dotatate
• Custom — custom products for clinical trials
— WHY IS THIS NEEDED?
Lutetium-177 Dotatate — widely used radiopharmaceutical for neuroendocrine tumor therapy:
• Lu-177 half-life: 6.65 days — optimal for therapy
• Beta radiation (0.497 MeV max) — effective tumor cell destruction
• Gamma radiation (113 and 208 keV) — allows imaging (SPECT/CT)
• Dotatate — somatostatin analog, binds to SSTR2 receptors on tumor cells
• Clinically proven efficacy in progressive GEP-NETs
⚠️ CRITICAL:
• Radiochemical purity ≥95% — ensures radiation delivery to tumor cells
• Free Lu-177 ≤2% — UNBOUND lutetium accumulates in BONE MARROW, causing myelosuppression!
• Colloidal Lu-177 ≤1% — COLLOIDS accumulate in liver and spleen, causing toxicity!
• Specific activity ≥40 GBq/μmol — ensures sufficient therapeutic dose
• pH 3.5-5.5 — critical for complex stability and blood compatibility
• Endotoxins ≤175 EU/vial — critical for IV administration!
• Sterility — MANDATORY for all parenteral forms!
• Radionuclidic purity ≥99.9% — minimizes non-target irradiation
• Lu-177m impurity ≤0.05% — CRITICAL! Lu-177m (T½=160 days) creates PROLONGED RADIATION BURDEN without therapeutic benefit
Key features:
• Check of all lutetium-177 forms (bound, free, colloidal)
• Specific activity control for therapeutic efficacy
• Specific control of Lu-177m impurity (metastable state)
• Support for different commercial products (Lutathera, generics, custom)
• Comprehensive check of radionuclidic and radiochemical parameters
Critical parameters:
• Radiochemical purity: ≥95.0%
• Free Lu-177: ≤2.0%
• Colloidal Lu-177: ≤1.0%
• Specific activity: ≥40 GBq/μmol
• pH: 3.5–5.5
• Endotoxins: ≤175 EU/vial
• Sterility: no microbial growth
• Radionuclidic purity: ≥99.9%
• Lu-177m impurity: ≤0.05%
💡 Usage tips:
1. Radiochemical purity controlled by HPLC or TLC
2. Free and colloidal Lu-177 separated by chromatography methods
3. Lu-177m determined by gamma spectrometry (228 keV peak)
4. Specific activity calculated from measured activity and peptide amount
5. If free Lu-177 >2% detected — batch rejected (myelosuppression risk)!
6. Lu-177m especially dangerous due to 160-day half-life — even 0.05% is unacceptable!
⚠️ Note: Lu-177 Dotatate is ONE OF THE MOST EFFECTIVE therapeutic radiopharmaceuticals for neuroendocrine tumors. Product quality is critically important: free lutetium causes myelosuppression, colloidal causes hepatotoxicity, and Lu-177m creates unnecessary prolonged radiation burden. Control of all these parameters is MANDATORY for clinical use.URS & FS — User Requirements and Functional Specification
This document describes the controlled interface and behaviour of Lu177DotatateVariants_CommercialRadioligandProductMap for Lu.
Portal packages
Cardiology QC Suite, Global/API coverage extension, LabEx QC laboratory utilities, Lumex QC instrument utilities, Radiology QC Suite, Combined Radiopharma QC Suite, World API/FDC extension
AntihypertensiveCSV→JSONCardiologyFDCLipid-loweringMissingAPIPolypillQCRPHRadioligandRadiologyRadiopharmaURS & FSP2Domain limits and critical parameters
- ℹ️ Utility checks critical parameters of lutetium-177 dotatate:
- • Radiochemical purity (≥95%)
- • Free Lu-177 (≤2%)
- • Colloidal Lu-177 (≤1%)
- • Specific activity (≥40 GBq/μmol)
- • Endotoxins (≤175 EU/vial)
- • Sterility
- • Radionuclidic purity (≥99.9%)
- • Lu-177m impurity (≤0.05%)
- ⚠️ CRITICAL: Free Lu-177 accumulates in bone marrow!
- BatchNumber,CommercialProduct,RadiochemicalPurityPercent,FreeLu177Percent,ColloidalLu177Percent,SpecificActivityGBqPerUmol,pH,EndotoxinsEUPerVial,SterilityTest,RadionuclidicPurityPercent,Lu177mImpurityPercent
- Example (sterility: 0=sterile, 1=contaminated):
- ⚠️ CRITICAL:
- • Radiochemical purity ≥95% — ensures radiation delivery to tumor cells
- • Free Lu-177 ≤2% — UNBOUND lutetium accumulates in BONE MARROW, causing myelosuppression!
- • Colloidal Lu-177 ≤1% — COLLOIDS accumulate in liver and spleen, causing toxicity!
- • Specific activity ≥40 GBq/μmol — ensures sufficient therapeutic dose
- • pH 3.5-5.5 — critical for complex stability and blood compatibility
URS — User Requirements Specification
| ID | Requirement | Criticality | Acceptance criterion |
|---|---|---|---|
| URS-001 | The utility shall accept an input.csv file for Lu with headers defined in the data contract. | High | The file is processed without manual header editing. |
| URS-002 | The utility shall perform deterministic QC evaluation without machine learning and without probabilistic conformance decisions. | High | Identical input data, rule version and configuration produce reproducible results. |
| URS-003 | The utility shall validate mandatory fields, data types, ranges, units and domain plausibility. | High | Schema, conversion and range errors are explicitly reported. |
| URS-004 | The utility shall apply domain limits and rules from the description, approved specification, registration dossier and local SOPs. | High | Each check has PASS/WARNING/FAIL and a clear message. |
| URS-005 | The utility shall generate output.json with machine-readable results, source values, warnings, failures and critical findings. | High | JSON is suitable for LIMS/ELN/MES integration and QA/QC review. |
| URS-006 | The utility shall preserve traceability between batch/sample, input file, applied rules and final status. | High | Output contains identifiers, checked parameters and audit metadata. |
| URS-007 | The documentation shall support IQ/OQ/PQ, CSV/CSA and review by internal QA or inspectors. | Medium | URS, FS, input/output contract and test scenarios are supplied with the utility. |
| URS-008 | The utility shall be used as a QC decision-support tool and not as a substitute for approved specifications and QA/QP release decision. | Medium | Documentation states change control and limit-verification expectations. |
input.csv contract
| # | Field | Type | Sample | Purpose |
|---|---|---|---|---|
| 1 | BatchNumber | string / controlled vocabulary | LU177-DOTA-2026-001 | Batch or lot identifier used for traceability. |
| 2 | CommercialProduct | string / controlled vocabulary | Lutathera | Product or dosage-form name under evaluation. |
| 3 | RadiochemicalPurityPercent | decimal | 99.2 | Controlled input parameter for deterministic QC rules. |
| 4 | FreeLu177Percent | decimal | 0.5 | Controlled input parameter for deterministic QC rules. |
| 5 | ColloidalLu177Percent | decimal | 0.3 | Controlled input parameter for deterministic QC rules. |
| 6 | SpecificActivityGBqPerUmol | decimal | 55.0 | Controlled input parameter for deterministic QC rules. |
| 7 | pH | decimal | 4.5 | pH; parameter relevant to stability, compatibility and batch suitability. |
| 8 | EndotoxinsEUPerVial | decimal | 45.0 | Microbiological/endotoxin parameter relevant to safety. |
| 9 | SterilityTest | decimal | 0 | Microbiological/endotoxin parameter relevant to safety. |
| 10 | RadionuclidicPurityPercent | decimal | 99.95 | Controlled input parameter for deterministic QC rules. |
| 11 | Lu177mImpurityPercent | decimal | 0.02 | Impurity/related-substance parameter; purity and degradation control. |
BatchNumber,CommercialProduct,RadiochemicalPurityPercent,FreeLu177Percent,ColloidalLu177Percent,SpecificActivityGBqPerUmol,pH,EndotoxinsEUPerVial,SterilityTest,RadionuclidicPurityPercent,Lu177mImpurityPercent LU177-DOTA-2026-001,Lutathera,99.2,0.5,0.3,55.0,4.5,45.0,0,99.95,0.02 LU177-DOTA-2026-002,Generic,97.8,1.2,0.5,48.0,4.2,80.0,0,99.92,0.03 LU177-DOTA-2026-003,Custom,96.5,1.8,0.8,42.0,4.8,120.0,0,99.90,0.04
Input validation rules
| ID | Field | Rule | Criticality |
|---|---|---|---|
| VR-001 | BatchNumber | The field shall match an approved dictionary or accepted string representation. | High |
| VR-002 | CommercialProduct | The field shall match an approved dictionary or accepted string representation. | High |
| VR-003 | RadiochemicalPurityPercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-004 | FreeLu177Percent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-005 | ColloidalLu177Percent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-006 | SpecificActivityGBqPerUmol | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-007 | pH | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-008 | EndotoxinsEUPerVial | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-009 | SterilityTest | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
| VR-010 | RadionuclidicPurityPercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | Medium |
| VR-011 | Lu177mImpurityPercent | The value shall be numeric, non-empty and domain-plausible for the approved specification. | High |
FS — Functional Specification
| ID | Function | Implementation |
|---|---|---|
| FS-001 | CLI execution | Support execution modes: demo mode without arguments and production mode input.csv output.json. |
| FS-002 | CSV import | Read input.csv in UTF-8/CSV-compatible format and validate header and expected columns. |
| FS-003 | Schema validation | Check mandatory fields, column count, unknown key fields and empty mandatory values. |
| FS-004 | Type conversion | Convert numeric, flag and text values; invalid format is recorded as a row-level error. |
| FS-005 | Domain rule engine | Apply rules for Lu, including critical limits from the description and approved specification. |
| FS-006 | Status aggregation | Produce final status: FAIL for critical failure, WARNING for non-critical deviation, PASS for conformance. |
| FS-007 | JSON export | Write output.json with detailed checks, source values, warnings, failures and critical findings. |
| FS-008 | Audit support | Keep result structure suitable for review, deviation investigation and calculation reproduction. |
| FS-009 | Integration contract | Support the scenario LIMS/ELN/MES → input.csv → utility → output.json → portal/admin review. |
| FS-010 | Fallback mapping | For a single API or modality, use this specialized utility together with applicable Lumex/LabEx instrumental checks. |
| FS-011 | Error handling | Return explicit messages for missing file, empty CSV, invalid schema, output write failure and invalid format. |
Example output.json
{
"utilityId": "lu-177-dotatate-variants-commercial-radioligand-product-map",
"utilityFolder": "Lu177DotatateVariants_CommercialRadioligandProductMap",
"package": "Cardiology QC Suite",
"overallStatus": "PASS|WARNING|FAIL",
"sourceFile": "input.csv",
"processedAtUtc": "2026-07-02T00:00:00Z",
"checks": [
{
"parameter": "BatchNumber",
"value": "LU177-DOTA-2026-001",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-001"
},
{
"parameter": "CommercialProduct",
"value": "Lutathera",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-002"
},
{
"parameter": "RadiochemicalPurityPercent",
"value": "99.2",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-003"
},
{
"parameter": "FreeLu177Percent",
"value": "0.5",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-004"
},
{
"parameter": "ColloidalLu177Percent",
"value": "0.3",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-005"
},
{
"parameter": "SpecificActivityGBqPerUmol",
"value": "55.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-006"
},
{
"parameter": "pH",
"value": "4.5",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-007"
},
{
"parameter": "EndotoxinsEUPerVial",
"value": "45.0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-008"
},
{
"parameter": "SterilityTest",
"value": "0",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-009"
},
{
"parameter": "RadionuclidicPurityPercent",
"value": "99.95",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-010"
},
{
"parameter": "Lu177mImpurityPercent",
"value": "0.02",
"status": "PASS|WARNING|FAIL",
"message": "Deterministic rule-based check result",
"ruleReference": "FS-RULE-011"
}
],
"criticalFindings": [],
"warnings": [],
"audit": {
"inputHash": "sha256:<calculated at runtime>",
"rulesVersion": "<utility executable version>",
"documentation": "Lu177DotatateVariants_CommercialRadioligandProductMap.documentation.html"
}
}
Traceability matrix
| URS | FS | Test | Evidence |
|---|---|---|---|
| URS-001 | FS-001, FS-002 | OQ-001 | Verify execution and import of valid input.csv. |
| URS-002 | FS-005, FS-006 | OQ-004 | Repeat the same dataset and compare output.json. |
| URS-003 | FS-003, FS-004, FS-011 | OQ-002, OQ-003 | Verify missing columns and invalid types. |
| URS-004 | FS-005, FS-006 | OQ-004, PQ-001 | Verify critical deviations on real/boundary data. |
| URS-005 | FS-007, FS-009 | OQ-005 | Verify JSON schema and downstream-system suitability. |
| URS-006 | FS-008 | OQ-006 | Verify identifiers and audit metadata. |
| URS-007 | FS-008, FS-011 | IQ-001, OQ-007 | Verify documentation completeness and control evidence. |
| URS-008 | FS-005, FS-008, FS-010 | PQ-002 | Verify review workflow and no replacement of QA decision. |
IQ/OQ/PQ test scenarios
| ID | Scenario | Expected result |
|---|---|---|
| IQ-001 | Verify executable, input.csv, documentation and checksum availability. | Delivery set is complete; version is recorded. |
| OQ-001 | Valid sample row from input.csv. | PASS or acceptable WARNING according to rules. |
| OQ-002 | Remove a mandatory CSV column. | Schema error or FAIL with missing-column reference. |
| OQ-003 | Place a non-numeric value into a numeric field. | Type-conversion error with row/field reference. |
| OQ-004 | Set a critical parameter outside the limit. | FAIL and critical finding. |
| OQ-005 | Verify output.json structure. | All mandatory sections are present and JSON is valid. |
| OQ-006 | Verify batch/sample traceability. | Input and result identifiers match. |
| OQ-007 | Verify fallback/decomposition for combined APIs. | Component checks are explicitly documented. |
| PQ-001 | Verify 3–5 real user batches/samples. | Result is confirmed by QC/QA review. |
| PQ-002 | Verify deviation workflow and manual QA decision. | Utility supports review but does not replace approved decision. |
QA/QC and change control
- Do not rename columns without updating validator, documentation and test set.
- Retain input.csv, output.json, executable version and checksum.
- Before production use, perform IQ/OQ/PQ or equivalent CSV/CSA verification.
- Critical limits shall be verified against the approved specification, registration dossier and local SOPs.
- For combination products, document whether the specialized FDC utility or fallback component checks were used.
- The utility provides structured QC decision support; final release decision remains with QA/QP and approved procedures.
Included in packages
Cardiology QC Suite
QC package for cardiology medicines: antihypertensives, anticoagulants, antiplatelets, lipid-lowering and antiarrhythmic medicines plus supporting QC checks.
OpenGlobal API & Biosimilars QC Suite
Package for high-demand global APIs, generics and biosimilars, including fixed-dose combinations and biological products.
OpenRadiology QC Suite
QC package for radiology and diagnostic imaging: radiopharmaceuticals, PET/SPECT, contrast media, iodinated and gadolinium products, plus particle, sterility and endotoxin checks.
OpenRPH isotope family: beta-emitting therapy
Lu-177, Y-90, Ho-166, Re-188, Sm-153, Sr-89, P-32, Cu-67 and Tb-161.
OpenRPH organ/system: bone and musculoskeletal
Bone scintigraphy, MDP/PYP, marrow, bone-pain palliation, skeletal metastases and radiosynovectomy.
OpenRPH organ/system: brain and CNS
Brain perfusion, dopamine transporter, amyloid/tau, receptor imaging and neurological SPECT/PET.
OpenRPH organ/system: endocrine, thyroid and NET
Radioiodine, thyroid/parathyroid, somatostatin receptor, MIBG and neuroendocrine workflows.
OpenRPH organ/system: hepatobiliary and GI
HIDA, mebrofenin, gallbladder, gastric emptying, GI transit, bleeding and liver/spleen imaging.
OpenRPH organ/system: oncology and theranostics
Tumour imaging, PSMA/FAPI/receptor tracers, immuno-PET, targeted radionuclide therapy and radioembolization.
OpenRPH use case: radionuclide therapy and theranostics
Lu-177, Ac-225, Ra-223, Y-90, Ho-166, Sm-153, Sr-89, Re-188, Tb-161, I-131 and other therapeutic radiopharmaceuticals: activity, purity, free metal, daughters and toxicological constraints.
OpenRPH workflow: generators and isotope purity
Generator eluate, breakthrough, radionuclidic purity, isotope mix and starting radionuclides.
OpenRPH workflow: imaging QC and quantitative interpretation
Acquisition, uptake, clearance, perfusion, transit, ejection fraction, segmentation and quantitative imaging.
OpenRPH workflow: product release QC
Assay, purity, sterility, endotoxins, pH, impurities, appearance and batch-release checks.
OpenRPH workflow: stability, storage, decay and waste
Kinetic stability, shelf life, decay correction, expiry, storage, trend and radioactive waste.
OpenRPH: combined radiopharmaceutical QC package
RPH combines PetRad, PetRad2 and PetRad3 into one umbrella package for PET/SPECT, therapeutic radionuclides, generators, labelled compounds, decay calculations, sterility, endotoxins and radiochemical/radionuclidic purity.
OpenWorld API Extension QC Suite
Extended package for 130 additional high-demand APIs and biological products prepared as a market-coverage backlog.
Open